贝那利珠单抗治疗嗜酸性粒细胞疾病儿童的试验 (CLIPS)
评估贝那利珠单抗治疗嗜酸性粒细胞疾病儿童的安全性、药代动力学和疗效的 3 期开放标签试验 (CLIPS)
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
研究概览
详细说明
This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.
Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.
Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.
The study consists of 3 periods:
- Screening period: 1 to 4 weeks
- Open-label treatment period: 52 weeks
- Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)
All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.
All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
学习地点
-
-
-
Petah Tikva、以色列、49202
- 招聘中
- Research Site
-
-
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G1X8
- 招聘中
- Research Site
-
-
-
-
-
Ahmedabad、印度、380052
- 招聘中
- Research Site
-
-
-
-
-
Altındağ、土耳其(türkiye)、06230
- 招聘中
- Research Site
-
Istanbul、土耳其(türkiye)、34093
- 招聘中
- Research Site
-
-
-
-
-
Guadalajara、墨西哥、44620
- 招聘中
- Research Site
-
-
-
-
-
São Paulo、巴西、01232-010
- 招聘中
- Research Site
-
-
-
-
-
Lille、法国、59037
- 招聘中
- Research Site
-
Montpellier、法国、34295
- 暂停
- Research Site
-
-
-
-
-
Kielce、波兰、25-734
- 招聘中
- Research Site
-
Warsaw、波兰、04-730
- 尚未招聘
- Research Site
-
-
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- Research Site
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- 招聘中
- Research Site
-
Highland Hills、Ohio、美国、44106-2624
- 招聘中
- Research Site
-
-
-
-
-
Rotterdam、荷兰、3015 GD
- 招聘中
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
All Cohorts:
- Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
- Body weight greater than (>=) 15 kilograms (kg).
EGPA Cohort:
- Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
- Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).
HES Cohort:
- Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
- Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
- AEC ≥1000 cells/µL at screening (Visit 1).
- Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.
Exclusion Criteria:
All Cohorts:
- Any current malignancy or history of malignancy.
- History of anaphylaxis to any biologic therapy or vaccine.
- Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
- Previous receipt of benralizumab in an interventional clinical study.
EGPA Cohort:
- Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
- EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
- Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.
HES Cohort:
- Life-threatening HES or HES complications, as judged by the investigator.
- Hypereosinophilia of unknown significance (HE-US).
- Diagnosis of systemic mastocytosis.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:EGPA/HES Cohort: Benralizumab
Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period. |
Benralizumab will be administered as SC injection on Q4W.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
大体时间:From screening (Week -4 to -1) until Week 52
|
The safety and tolerability of benralizumab will be evaluated. |
From screening (Week -4 to -1) until Week 52
|
|
Serum Concentrations of Benralizumab
大体时间:Weeks 0, 12, 24, 25, 36, and 52
|
The PK of benralizumab will be evaluated. |
Weeks 0, 12, 24, 25, 36, and 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
EGPA Cohort: Percentage of Participants with Remission at Week 24
大体时间:At Week 24
|
Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day. |
At Week 24
|
|
Number of Participants with Positive Antidrug Antibody (ADA)
大体时间:Weeks 0, 12, 24, 36, 48, and 52
|
The immunogenicity of benralizumab will be evaluated. |
Weeks 0, 12, 24, 36, 48, and 52
|
|
Change From Baseline in Peripheral Blood Eosinophil Count
大体时间:From Baseline to Weeks 0, 12, 24, 36, 52
|
The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated. |
From Baseline to Weeks 0, 12, 24, 36, 52
|
|
EGPA Cohort: Time to First EGPA Relapse
大体时间:Up to 52 weeks
|
The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening. |
Up to 52 weeks
|
|
HES Cohort: Time to first HES worsening/flare
大体时间:Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Percentage of participants who experience a HES worsening/flare
大体时间:Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Number of HES worsening/flares (annualised rate/year)
大体时间:Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows: The total number of flares *365.25 / total duration of follow-up in the treatment period (days). |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
大体时间:Up to 52 weeks
|
The effect of benralizumab on corticosteroid use will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Time to first haematologic relapse
大体时间:Up to 52 weeks
|
The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL. |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants with haematologic relapse
大体时间:Up to 52 weeks
|
The effect of benralizumab on haematologic measures of disease activity will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
大体时间:Up to 52 weeks
|
The effect of benralizumab on haematologic measures of disease activity will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Patient Global Impression of Change (PGI-C) Score
大体时间:Weeks 12, 24, 36 and 48
|
The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse'). |
Weeks 12, 24, 36 and 48
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- D3255C00004
- 2023-508533-14-00 (其他标识符:EU CT)
- EMEA-001214-PIP09-21-M02(EGPA) (其他标识符:Paediatric Investigational Plan Number)
- EMEA-001214-PIP04-19-M02 (HES) (其他标识符:Paediatric Investigational Plan Number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.